Ponatinib

BreastfeedingPediatric
  • TRADE NAME: Iclusig (Ariad)
  • INDICATIONS: Chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor therapy
  • CLASS: Tyrosine kinase inhibitor
  • HALF-LIFE: 24 hours

FDA APPROVAL DATE: 12/14/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antacids, Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Grapefruit Juice, Histamine H2 antagonists, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Proton pump inhibitors, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors or inducers, Telaprevir, Telithromycin, Voriconazole

PREGNANCY CATEGORY: D

VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY

See full prescribing information for complete boxed warning.

Our database has 85 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top